Albert David logo

Albert David

ALBERTDAVD NSE
₹772.00 3.70 (0.48%)
Market Cap
₹441 Cr
P/E
19.52

Albert David (ALBERTDAVD) share price was ₹772.00 at the 28 Oct 2026 close; market capitalisation ₹441 Cr; P/E (TTM) 19.52; sector Healthcare. The share price fell 7.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 43.5% year on year to ₹101.3 Cr and net profit was ₹32 Cr, against ₹8 Cr a year earlier (compared with Jun 2025). Promoters held 62.24% of Albert David in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 55/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹772.00 −66.10 −7.89% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹441 Cr
P/E (TTM)
19.52
EBITDA
₹12.90 Cr
Return on Equity
-0.38%
Debt to Equity
0.08
Book Value
₹685.71
EPS (TTM)
₹39.55
52W High
₹931.85
52W Low
₹579.90

Price-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Albert David (this company)
₹772.0019.52441 Cr1.130.64%-0.38%0.78%378 Cr23 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.63%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
55 Good
Overall score
Data confidence 100/100

Category scores

Quality Average 46
Returns, margins, earnings quality 22%
Valuation Good 57
Cheap vs sector & own history 24%
Growth Average 53
Sales & profit trajectory 9%
Financial Health Strong 67
Solvency, leverage, coverage 9%
Momentum Strong 67
Trend strength, vol-adjusted 12%
Ownership Average 51
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

3
  • The company has delivered a poor sales growth of 6.20% over past five years.
  • Company has a low return on equity of 8.03% over last 3 years.
  • Earnings include an other income of Rs.13.4 Cr.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

BearishNeutralBullish

Bearish

Bearish
11
Neutral
7
Bullish
1

Moving Averages

BearishNeutralBullish

Bearish

Bearish
9
Neutral
0
Bullish
1

Growth Rate

Revenue Growth
-9.11% lower than 3Y

change over 1 year

Net Income Growth
-109% lower than 3Y

change over 1 year

Cash Flow Change
73.07%

change over 1 year

EBITDA Margin Change
-56.39%

change over 1 year Operating margin 10% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
92
93
88
89
89
98
83
75
71
87
90
86
101
Expenses
79
77
80
79
88
92
82
80
81
85
79
83
91
Operating Profit
13
16
8
10
1
6
1
-5
-11
3
11
3
11
OPM %
14%
17%
9%
11%
1%
6%
0.8%
-6%
-15%
2.9%
12%
3.2%
10%
Other Income
18
12
17
10
23
21
-9
-5
22
-2
12
-25
28
Interest
0
0
0
0
0
0
0
0
1
1
1
0
1
Depreciation
2
1
2
2
2
2
2
2
2
2
2
3
2
PBT
29
27
23
18
22
25
-10
-12
8
-3
20
-25
36
Tax %
20%
24%
20%
29%
15%
28%
-8%
-13%
6%
28%
23%
-15%
11%
Net Profit
23
20
19
13
19
18
-9
-10
8
-3
15
-21
32
EPS (₹)
41.16
35.57
32.8
22.62
33.01
31.66
-16.45
-18.1
13.91
-5.78
26.81
-37.55
56.07
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
317
318
293
285
316
320
246
313
341
362
345
333
364
Expenses
281
286
266
267
286
289
227
272
297
315
342
327
338
Operating Profit
37
31
27
18
30
30
19
41
44
47
3
6
27
OPM %
12%
10%
9%
6%
10%
10%
8%
13%
13%
13%
0.9%
1.7%
7%
Other Income
2
43
8
9
15
7
17
16
15
58
30
7
13
Interest
3
2
1
1
1
1
1
1
1
0
1
3
3
Depreciation
15
9
8
8
7
8
8
9
9
7
7
10
10
PBT
20
63
26
18
38
29
27
47
51
97
25
1
28
Tax %
32%
24%
39%
45%
29%
34%
19%
25%
29%
22%
32%
379%
—
Net Profit
14
48
16
10
27
19
22
35
36
75
17
-1
23
EPS (₹)
24
84.1
27.96
17.24
46.68
33.59
38.79
61.78
63.38
132
30.14
-2.61
39.55
Div. Payout %
23%
7%
20%
32%
13%
21%
15%
15%
14%
9%
17%
-192%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6
6
6
6
6
6
6
6
6
6
6
6
Reserves
87
131
177
180
205
217
239
274
306
377
387
386
Borrowings
30
20
30
28
0
2
2
6
5
3
12
30
Other Liabilities
71
67
71
76
84
95
95
116
106
112
107
98
Total Liabilities
193
224
285
290
295
320
341
401
423
498
511
519
Fixed Assets
49
44
87
83
77
91
84
88
80
83
99
100
CWIP
5
5
9
5
5
2
1
1
3
7
2
21
Investments
16
48
59
68
113
122
138
183
193
273
260
243
Other Assets
122
127
130
134
99
106
119
130
148
135
151
155
Total Assets
193
224
285
290
295
320
341
401
423
498
511
519
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
28
68
20
30
32
30
37
40
11
46
-28
-8
Investing
-9
-38
-36
-11
-19
-20
-37
-40
-5
-33
23
-4
Financing
-18
-18
7
-5
-17
-10
-2
-2
-6
-8
0
12
Net Cash Flow
1
12
-10
15
-4
0
-2
-1
-1
4
-5
0
Free Cash Flow
18
62
0
31
45
15
35
32
6
35
-43
-36
CFO/EBITDA
95
303
115
204
126
149
202
129
59
131
-629
-47
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
47
41
41
35
25
34
29
29
32
30
29
37
Inventory Days
176
187
217
173
151
148
151
124
149
126
201
187
Days Payable
103
102
117
127
102
132
104
96
95
98
118
104
Cash Conversion Cycle
120
126
141
81
74
50
76
57
87
58
112
120
Working Capital Days
27
25
24
10
21
18
-10
-34
14
-13
6
1
ROCE %
18%
17%
15%
7%
18%
14%
12%
17%
17%
28%
6%
1%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Albert David insights

64 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

FIIs0.60%Promot.62.24%DIIs1.64%Others7.61%Public27.92%As ofSep 2026

Documents

Frequently Asked Questions about Albert David

What does Albert David Ltd do?
Incorporated in 1938, Albert David Ltd is in the business of manufacturing pharmaceutical products[1]
Where is Albert David Ltd (ALBERTDAVD) listed?
Albert David Ltd trades as ALBERTDAVD on the NSE and under code 524075 on the BSE.
Which sector does Albert David Ltd belong to?
Albert David Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Albert David Ltd?
Albert David Ltd has a market capitalisation of ₹440.59 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Albert David Ltd?
Albert David Ltd trades at a PE ratio of 19.52 as of 28 Oct 2026, on earnings per share of ₹39.55, against a book value of ₹685.71 per share.
What is the 52-week high and low of Albert David Ltd?
Over the last 52 weeks Albert David Ltd has traded between ₹579.9 and ₹931.85 as of 28 Oct 2026.
Does Albert David Ltd pay dividends?
Albert David Ltd has a dividend yield of 0.64%.
What is the Return on Equity (ROE) of Albert David Ltd?
Albert David Ltd reported a return on equity of -0.38%. Its debt-to-equity ratio is 0.08.

Company Information

Incorporated in 1938, Albert David Ltd is in the business of manufacturing pharmaceutical products[1]

Website albertdavidindia.com
CEO Mr. Arun Kumar Kothari
Employees 1,805
Listed 1996-06-14
Face Value ₹ 10
Shares Outstanding 57,07,162

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALBERTDAVD.md for Albert David Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month